Global Neuropathic Pain Market, By Type (Spinal Cord Stimulation (SCS) Devices, External Peripheral Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation (TENS) Devices, Focal Neuropathy, Automatic Neuropathy, and Proximal Neuropathy), Product Type (Rechargeable and Non-Rechargeable), Procedure (Invasive and Non-Invasive), Technology (Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation, and Respiratory Electrical Stimulation), Modality (Stationary and Portable), Mode of Purchase (Over-the-Counter Devices and Prescription-Based Devices), Pain Type (Peripheral Neuropathy, Entrapment Neuropathy, Phantom Limb Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, Foot Pain, and Coccydynia), Indication (Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy, and Others), Diagnosis (Imaging, Blood Tests, and Physical Examination) Treatment ( Medications, and Multimodal Therapy) End User (Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Research Organization, and Others), Distribution Channel (Direct Tender, Third Party Distributor and Others) – Industry Trends and Forecast to 2031.
Neuropathic Pain Market Analysis and Size
As per the 2021 International Diabetes Federation (IDF) report, 537 million adults aged 20-79 globally had diabetes. Projections indicate a rise to 643 million by 2030 and 783 million by 2045. This escalating prevalence of diabetes, a major contributor to neuropathic pain, underscores the demand for therapeutic interventions, driving growth in the neuropathic pain market.
Data Bridge Market Research analyses that the global neuropathic pain market, which was USD 5.86 billion in 2023, is expected to reach USD 11.86 billion by 2031, and is expected to undergo a CAGR of 9.2% during the forecast period of 2024 to 2031. This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Spinal Cord Stimulation (SCS) Devices, External Peripheral Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation (TENS) Devices, Focal Neuropathy, Automatic Neuropathy, and Proximal Neuropathy), Product Type (Rechargeable and Non-Rechargeable), Procedure (Invasive and Non-Invasive), Technology (Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation, and Respiratory Electrical Stimulation), Modality (Stationary and Portable), Mode of Purchase (Over-the-Counter Devices and Prescription-Based Devices), Pain Type (Peripheral Neuropathy, Entrapment Neuropathy, Phantom Limb Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, Foot Pain, and Coccydynia), Indication (Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy, and Others), Diagnosis (Imaging, Blood Tests, and Physical Examination) Treatment ( Medications, and Multimodal Therapy) End User (Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Research Organization, and Others), Distribution Channel (Direct Tender, Third Party Distributor and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
NEVRO CORP. (U.S.), Lilly (U.S.), Astellas Pharma Inc. (Japan), Biogen (U.S.), Cirtec (U.S.), Integer Holdings Corporation (U.S.), B. Braun SE (Germany), Medtronic (Ireland), Abbott (U.S.), Boston Scientific Corporation (U.S.), OMRON Healthcare Co., Ltd. (Japan), electroCore, Inc. (U.S.), Polar Medical Ltd (U.K.), SunMED Medical (U.S.), NeuroMetrix, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Neuropathic pain is a type of chronic pain caused by damage or dysfunction of the nervous system. It often presents as burning, shooting, or electric shock-kind of sensations, and may be accompanied by numbness or tingling. Conditions such as diabetes, nerve injury, and certain diseases can lead to neuropathic pain, which can be challenging to manage.
Global Neuropathic Pain Market Dynamics
Drivers
- Increasing Prevalence in Aging Population
With the aging global population, the incidence of conditions associated with neuropathic pain, such as neuropathy, rises. This demographic shift fuels a greater demand for effective neuropathic pain management solutions, reflecting the need for comprehensive healthcare strategies to address the challenges of an aging society.
- Government Initiatives for Neuropathic Pain Treatments
Supportive regulatory frameworks and expedited approval processes for neuropathic pain treatments foster innovation and research and development investment. This encourages pharmaceutical companies to develop new therapies, driving market growth by ensuring timely access to effective treatments and expanding the range of options available to patients suffering from neuropathic pain.
Opportunities
- Patient-Centric Care for Effective Result
The shift towards patient-centric care and personalized medicine in neuropathic pain management fosters tailored treatment approaches. Through prioritizing individual patient needs and preferences, healthcare providers develop more effective and holistic strategies, improving patient outcomes and satisfaction in addressing the complexities of neuropathic pain
- Rising Chronic Pain Management Programs
The growing emphasis on comprehensive chronic pain management programs, integrating interdisciplinary approaches and holistic interventions, caters to the multifaceted nature of neuropathic pain. This trend propels demand for associated products and services, reflecting a shift towards more effective and better solutions in addressing neuropathic pain.
Restraints/Challenges
- Psychosocial Factors Impact Treatment Effect
Psychosocial factors such as depression, anxiety, and socioeconomic status pose challenges for the neuropathic pain market by complicating treatment outcomes. These variables can influence patients' perception of pain severity and response to therapy, making it difficult for pharmaceutical companies to develop targeted treatments and leading to heterogeneous treatment responses among individuals with neuropathic pain.
- Side Effects and Health Concerns During Treatment
Safety concerns and side effects linked to conventional neuropathic pain treatments such as opioids and certain antidepressants undermine market growth. Patient reluctance due to potential adverse reactions and limited long-term use impacts treatment adherence and market growth. This deters investment in such medications and fosters demand for safer, more tolerable therapeutic alternatives.
This global neuropathic pain market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global neuropathic pain market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In September 2022, AlgoTx commenced a phase 2 clinical trial for ATX01, a topical amitriptyline, addressing chemotherapy-induced peripheral neuropathy (CIPN). Across 40 U.S. and Europe centers, the trial evaluates ATX01's efficacy for adults with CIPN, shaping the neuropathic pain market's growth
- In July 2022, Novaremed AG and NeuroFront Therapeutics (Hong Kong) Limited entered an exclusive collaboration for Novaremed's non-opioid investigational drug, NRD.E1, for diabetes-related and other neuropathic pain indications. The agreement entails substantial payments to Novaremed, signaling confidence in NRD.E1's potential for neuropathic pain management
- In December 2021, Boston Scientific Corporation launched the WaveWriter Alpha Spinal Cord Stimulator Systems for chronic pain, including neuropathic pain. This product release is poised to boost company revenue and market share, offering advanced treatment options for neuropathic pain patients
- In January 2021, Abbott's acquisition of St. Jude Medical, Inc. expanded its medical device market presence. This strategic move strengthened Abbott's product portfolio, positioning it for significant growth in the neuropathic pain market and other healthcare sectors, leveraging St. Jude Medical's expertise and resources
Global Neuropathic Pain Market Scope
The global neuropathic pain market is segmented on the basis of type, product type, procedure, technology, modality, mode of purchase, pain type, indication, treatment, diagnosis, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Spinal Cord Stimulation (SCS) Devices
- External Peripheral Nerve Stimulation
- Transcutaneous Electrical Nerve Stimulation (TENS) Devices
- Focal Neuropathy
- Automatic Neuropathy
- Proximal Neuropathy
Product Type
- Rechargeable
- Non-Rechargeable
Procedure
- Invasive
- Non-Invasive
Technology
- Transcutaneous Electrical Nerve Stimulation
- Transcranial Magnetic Stimulation
- Respiratory Electrical Stimulation
Modality
- Stationary
- Portable
Mode of Purchase
- Over-the-Counter Devices
- Prescription-Based Devices
Pain Type
- Peripheral Neuropathy
- Entrapment Neuropathy
- Phantom Limb Neuropathy
- Trigeminal Neuralgia
- Post Herpetic Neuralgia (PHN)
- Post Traumatic Neuropathy
- Foot Pain
- Coccydynia
Indication
- Spinal Stenosis
- Chemotherapy-Induced Peripheral Neuropathy
- Diabetic Neuropathy
- Others
Diagnosis
- Imaging
- Blood Tests
- Physical Examination
Treatment
- Medications
- Multimodal Therapy
End User
- Hospitals
- Clinics
- Home Healthcare
- Ambulatory Surgical Centers
- Research Organization
- Others
Distribution Channel
- Direct Tender
- Third Party Distributor
- Others
Global Neuropathic Pain Market Regional Analysis/Insights
The global neuropathic pain market is analysed and market size insights and trends are provided by country, type, product type, procedure, technology, modality, mode of purchase, pain type, indication, treatment, diagnosis, end user and distribution channel as referenced above.
The countries covered in the global neuropathic pain market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
In North America, the spinal cord stimulation segment is anticipated to exhibit the highest growth rate from 2024 to 2031, driven by an increasing demand for neuropathic pain devices in healthcare, reflecting the region's commitment to advanced medical solutions and the management of chronic pain.
In Asia-Pacific, China leads in the growth of the neuropathic pain market, attributed to a rising prevalence of chronic pain and notable technological advancements in the healthcare sector, emphasizing the country's pivotal role in shaping the landscape of neuropathic pain management in the Asia-Pacific region.
In Europe, U.K. dominates the neuropathic pain market, propelled by substantial advancements in healthcare expenditure and funding. The country's leadership position underscores its commitment to fostering innovation and accessibility in neuropathic pain treatment within the Europe market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The global neuropathic pain market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global neuropathic pain market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global neuropathic pain market. The data is available for historic period 2016-2021.
Competitive Landscape and Global Neuropathic Pain Market Share Analysis
The global neuropathic pain market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global neuropathic pain market.
Some of the major players operating in the global neuropathic pain market are:
- NEVRO CORP. (U.S.)
- Lilly (U.S.)
- Astellas Pharma Inc. (Japan)
- Biogen (U.S.)
- Cirtec (U.S.)
- Integer Holdings Corporation (U.S.)
- B. Braun SE (Germany)
- Medtronic (Ireland)
- Abbott (U.S.)
- Boston Scientific Corporation (U.S.)
- OMRON Healthcare Co., Ltd. (Japan)
- electroCore, Inc. (U.S.)
- Polar Medical Ltd (U.K.)
- SunMED Medical (U.S.)
- NeuroMetrix, Inc. (U.S.)
SKU-